NCOA4 and neoplasm: RET/PTC3 transcriptional products were found to be inhibited in tumours treated by siRNA RET/PTC3-SQ NPs (p<0.001) and these results were more significantly pronounced once we focused on RET/PTC3 protein expression in Western blot which was completely reduced (Fig. 6B and C).